Bevacizumab (Avastin®, Genentech, Inc.)is a recombinant, humanized monoclonal antibody that binds all isoforms of VEGF-A, and has been approved for the treatment of metastatic colorectal cancer, non-small-cell lung cancer, and glioblastoma multiforme [1, 25]. The gene discussed is VEGFA; the disease is metastatic colorectal cancer.